APAC Telehealth Leader MNDR Expects Revenue Growth in H12024 vs H12023 | SINGAPORE, April 22, 2024 (GLOBE NEWSWIRE) -- Mobile-health Network Solutions (Nasdaq: MNDR) ("Mobile-Health" or the "Company"), a pioneering Asia-Pacific ("APAC") telehealth provider, today provided... ► Artikel lesen |
Mobile-health Network Solutions Makes History as First APAC Telehealth Company Listed on US Stock Exchange | SINGAPORE, April 15, 2024 (GLOBE NEWSWIRE) -- Mobile-health Network Solutions (Nasdaq: MNDR), a pioneering Asia-Pacific (APAC) telehealth provider, celebrates its successful initial public offering... ► Artikel lesen |
Mobile-health Network Solutions Announces Closing of Initial Public Offering | SINGAPORE, April 12, 2024 (GLOBE NEWSWIRE) -- Mobile-health Network Solutions ("MNDR" or "the Company"), a leading telehealth solutions provider in Singapore, today announced the closing of its previously... ► Artikel lesen |
AtriCure Reports First Quarter 2024 Financial Results | MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and... ► Artikel lesen |
Seoul Robotics Explores Partnership in Industrial Autonomous Driving R&D with UAE's Advanced Technology Research Council (ATRC) | SEOUL, South Korea, March 11, 2024 /PRNewswire/ -- Seoul Robotics, a leading industrial autonomous driving company, recently engaged in discussions with Abu Dhabi's Advanced Technology Research... ► Artikel lesen |
AtriCure Reports Fourth Quarter 2023 and Full Year 2023 Financial Results | MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and... ► Artikel lesen |
BARCLAYS stuft Fresenius SE auf 'Overweight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat die Einstufung für Fresenius nach dem angekündigten Verkauf der Kontrollmehrheit von Reha-Kliniken an PAI Partners auf "Overweight"... ► Artikel lesen |
JEFFERIES stuft Fresenius SE auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Fresenius anlässlich des Verkaufs von 67 Prozent der Vamed-Reha-Kliniken auf "Buy" mit einem Kursziel von 40 Euro belassen.... ► Artikel lesen |
BERENBERG stuft Fresenius SE auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Fresenius anlässlich des Verkaufs von 67 Prozent der Vamed-Reha-Kliniken auf "Buy" mit einem Kursziel von 43 Euro belassen.... ► Artikel lesen |